322 related articles for article (PubMed ID: 9526813)
1. Role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors ("statins") in familial combined hyperlipidemia.
Schonfeld G; Aguilar-Salina C; Elias N
Am J Cardiol; 1998 Feb; 81(4A):43B-46B. PubMed ID: 9526813
[TBL] [Abstract][Full Text] [Related]
2. The magnitude of decrease in hepatic very low density lipoprotein apolipoprotein B secretion is determined by the extent of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition in miniature pigs.
Burnett JR; Wilcox LJ; Telford DE; Kleinstiver SJ; Barrett PH; Newton RS; Huff MW
Endocrinology; 1999 Nov; 140(11):5293-302. PubMed ID: 10537160
[TBL] [Abstract][Full Text] [Related]
3. A familial combined hyperlipidemic kindred with impaired apolipoprotein B catabolism. Kinetics of apolipoprotein B during placebo and pravastatin therapy.
Aguilar-Salinas CA; Hugh P; Barrett R; Pulai J; Zhu XL; Schonfeld G
Arterioscler Thromb Vasc Biol; 1997 Jan; 17(1):72-82. PubMed ID: 9012640
[TBL] [Abstract][Full Text] [Related]
4. Effects of simvastatin on plasma lipids and apolipoproteins in familial hypercholesterolemic swine.
Hasler-Rapacz J; Kempen HJ; Princen HM; Kudchodkar BJ; Lacko A; Rapacz J
Arterioscler Thromb Vasc Biol; 1996 Jan; 16(1):137-43. PubMed ID: 8548414
[TBL] [Abstract][Full Text] [Related]
5. Stable isotopes show a direct relation between VLDL apoB overproduction and serum triglyceride levels and indicate a metabolically and biochemically coherent basis for familial combined hyperlipidemia.
Venkatesan S; Cullen P; Pacy P; Halliday D; Scott J
Arterioscler Thromb; 1993 Jul; 13(7):1110-8. PubMed ID: 8318511
[TBL] [Abstract][Full Text] [Related]
6. Metabolism of plasma low density lipoproteins in familial combined hyperlipidaemia: effect of acipimox therapy.
Ericsson S; Eriksson M; Berglund L; Angelin B
J Intern Med; 1992 Oct; 232(4):313-20. PubMed ID: 1402634
[TBL] [Abstract][Full Text] [Related]
7. Physiologic mechanisms of action of lovastatin in nephrotic syndrome.
Aguilar-Salinas CA; Barrett PH; Kelber J; Delmez J; Schonfeld G
J Lipid Res; 1995 Jan; 36(1):188-99. PubMed ID: 7706943
[TBL] [Abstract][Full Text] [Related]
8. Familial combined hyperlipidemia in children: clinical expression, metabolic defects, and management.
Cortner JA; Coates PM; Liacouras CA; Jarvik GP
J Pediatr; 1993 Aug; 123(2):177-84. PubMed ID: 8345411
[TBL] [Abstract][Full Text] [Related]
9. Effects of gemfibrozil or simvastatin on apolipoprotein-B-containing lipoproteins, apolipoprotein-CIII and lipoprotein(a) in familial combined hyperlipidaemia.
Bredie SJ; Westerveld HT; Knipscheer HC; de Bruin TW; Kastelein JJ; Stalenhoef AF
Neth J Med; 1996 Aug; 49(2):59-67. PubMed ID: 8824106
[TBL] [Abstract][Full Text] [Related]
10. New dimension of statin action on ApoB atherogenicity.
Chapman MJ; Caslake M; Packard C; McTaggart F
Clin Cardiol; 2003 Jan; 26(1 Suppl 1):I7-10. PubMed ID: 12539816
[TBL] [Abstract][Full Text] [Related]
11. Expression of human apolipoprotein A-II in apolipoprotein E-deficient mice induces features of familial combined hyperlipidemia.
Escolà-Gil JC; Julve J; Marzal-Casacuberta A; Ordóñez-Llanos J; González-Sastre F; Blanco-Vaca F
J Lipid Res; 2000 Aug; 41(8):1328-38. PubMed ID: 10946021
[TBL] [Abstract][Full Text] [Related]
12. Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia.
Ellen RL; McPherson R
Am J Cardiol; 1998 Feb; 81(4A):60B-65B. PubMed ID: 9526816
[TBL] [Abstract][Full Text] [Related]
13. Influence of atorvastatin and simvastatin on apolipoprotein B metabolism in moderate combined hyperlipidemic subjects with low VLDL and LDL fractional clearance rates.
Forster LF; Stewart G; Bedford D; Stewart JP; Rogers E; Shepherd J; Packard CJ; Caslake MJ
Atherosclerosis; 2002 Sep; 164(1):129-45. PubMed ID: 12119202
[TBL] [Abstract][Full Text] [Related]
14. Effect of fluvastatin on intermediate density lipoprotein (remnants) and other lipoprotein levels in hypercholesterolemia.
Broyles FE; Walden CE; Hunninghake DB; Hill-Williams D; Knopp RH
Am J Cardiol; 1995 Jul; 76(2):129A-135A. PubMed ID: 7604788
[TBL] [Abstract][Full Text] [Related]
15. Pitavastatin: novel effects on lipid parameters.
Chapman MJ
Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
[TBL] [Abstract][Full Text] [Related]
16. Effects of fish oil concentrate on lipoproteins and apolipoproteins in familial combined hyperlipidemia.
Tatò F; Keller C; Wolfram G
Clin Investig; 1993 Apr; 71(4):314-8. PubMed ID: 8471818
[TBL] [Abstract][Full Text] [Related]
17. Apolipoprotein, low density lipoprotein subfraction, and insulin associations with familial combined hyperlipidemia. Study of Utah patients with familial dyslipidemic hypertension.
Hunt SC; Wu LL; Hopkins PN; Stults BM; Kuida H; Ramirez ME; Lalouel JM; Williams RR
Arteriosclerosis; 1989; 9(3):335-44. PubMed ID: 2497719
[TBL] [Abstract][Full Text] [Related]
18. Pravastatin effectively lowers LDL cholesterol in familial combined hyperlipidemia without changing LDL subclass pattern.
Franceschini G; Cassinotti M; Vecchio G; Gianfranceschi G; Pazzucconi F; Murakami T; Sirtori M; D'Acquarica AL; Sirtori CR
Arterioscler Thromb; 1994 Oct; 14(10):1569-75. PubMed ID: 7918306
[TBL] [Abstract][Full Text] [Related]
19. Effect of pravastatin and omega-3 fatty acids on plasma lipids and lipoproteins in patients with combined hyperlipidemia.
Contacos C; Barter PJ; Sullivan DR
Arterioscler Thromb; 1993 Dec; 13(12):1755-62. PubMed ID: 8241095
[TBL] [Abstract][Full Text] [Related]
20. A mouse model with features of familial combined hyperlipidemia.
Masucci-Magoulas L; Goldberg IJ; Bisgaier CL; Serajuddin H; Francone OL; Breslow JL; Tall AR
Science; 1997 Jan; 275(5298):391-4. PubMed ID: 8994037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
